Matches in SemOpenAlex for { <https://semopenalex.org/work/W3173084197> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W3173084197 endingPage "12078" @default.
- W3173084197 startingPage "12078" @default.
- W3173084197 abstract "12078 Background: Neuropathy is a common side effect of some chemotherapies. Clinical and other factors may confer neuropathy risk, but rates and risk factors across neuropathy-causing chemotherapies are incompletely understood. Methods: We examined 15 chemotherapy drugs known to confer neuropathy. Within a broad population of cancer patients who underwent treatment with these agents at the University of Chicago Medicine between 2012-2018, we determined prevalence of chemotherapy-induced neuropathy, defined as patients with initiation of a neuropathy treatment medication (amitriptyline, carbamazepine, duloxetine, gabapentin, or pregabalin) after starting chemotherapy. We then analyzed chemotherapy-induced neuropathy risk for different drugs and based on clinical demographic factors. Results: We analyzed 7,866 patients (65.3% White, 53.7% Female, 27.6% Black/African-American, 5.6% Hispanic or Latino, 3.1% Asian/Mideast Indian, 2.4% More than one Race, 0.2% American Indian or Alaska Native, 0.2% Native Hawaiian/Other Pacific Islander). The overall prevalence of chemotherapy-induced neuropathy was 24.3% across our patient population. Black/African-American patients had an increased risk of chemotherapy-induced neuropathy compared to the rest of the patient cohort (OR 1.4, 95% CI 1.3-1.6, P = 1.6e-10). Females also exhibited an increased risk of chemotherapy-induced neuropathy compared to males (OR 1.2, 95% CI 1.1-1.3, P = 1.5e-3). Conclusions: Certain chemotherapy agents confer substantial risk of chemotherapy-induced neuropathy, and risk is increased in Blacks and females. Future work will investigate additional risk-modifying factors including the potential role of germline polymorphisms on chemotherapy neuropathy risk.[Table: see text]" @default.
- W3173084197 created "2021-06-22" @default.
- W3173084197 creator A5018398274 @default.
- W3173084197 creator A5049759474 @default.
- W3173084197 creator A5070939740 @default.
- W3173084197 creator A5071502539 @default.
- W3173084197 date "2021-05-20" @default.
- W3173084197 modified "2023-09-24" @default.
- W3173084197 title "Investigating the prevalence and risk of chemotherapy-induced neuropathy among cancer patients." @default.
- W3173084197 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.12078" @default.
- W3173084197 hasPublicationYear "2021" @default.
- W3173084197 type Work @default.
- W3173084197 sameAs 3173084197 @default.
- W3173084197 citedByCount "0" @default.
- W3173084197 crossrefType "journal-article" @default.
- W3173084197 hasAuthorship W3173084197A5018398274 @default.
- W3173084197 hasAuthorship W3173084197A5049759474 @default.
- W3173084197 hasAuthorship W3173084197A5070939740 @default.
- W3173084197 hasAuthorship W3173084197A5071502539 @default.
- W3173084197 hasConcept C121608353 @default.
- W3173084197 hasConcept C126322002 @default.
- W3173084197 hasConcept C134018914 @default.
- W3173084197 hasConcept C141071460 @default.
- W3173084197 hasConcept C142724271 @default.
- W3173084197 hasConcept C143998085 @default.
- W3173084197 hasConcept C204787440 @default.
- W3173084197 hasConcept C2776608144 @default.
- W3173084197 hasConcept C2776694085 @default.
- W3173084197 hasConcept C2779289229 @default.
- W3173084197 hasConcept C2779901536 @default.
- W3173084197 hasConcept C2908647359 @default.
- W3173084197 hasConcept C555293320 @default.
- W3173084197 hasConcept C71924100 @default.
- W3173084197 hasConcept C99454951 @default.
- W3173084197 hasConceptScore W3173084197C121608353 @default.
- W3173084197 hasConceptScore W3173084197C126322002 @default.
- W3173084197 hasConceptScore W3173084197C134018914 @default.
- W3173084197 hasConceptScore W3173084197C141071460 @default.
- W3173084197 hasConceptScore W3173084197C142724271 @default.
- W3173084197 hasConceptScore W3173084197C143998085 @default.
- W3173084197 hasConceptScore W3173084197C204787440 @default.
- W3173084197 hasConceptScore W3173084197C2776608144 @default.
- W3173084197 hasConceptScore W3173084197C2776694085 @default.
- W3173084197 hasConceptScore W3173084197C2779289229 @default.
- W3173084197 hasConceptScore W3173084197C2779901536 @default.
- W3173084197 hasConceptScore W3173084197C2908647359 @default.
- W3173084197 hasConceptScore W3173084197C555293320 @default.
- W3173084197 hasConceptScore W3173084197C71924100 @default.
- W3173084197 hasConceptScore W3173084197C99454951 @default.
- W3173084197 hasIssue "15_suppl" @default.
- W3173084197 hasLocation W31730841971 @default.
- W3173084197 hasOpenAccess W3173084197 @default.
- W3173084197 hasPrimaryLocation W31730841971 @default.
- W3173084197 hasRelatedWork W14228319 @default.
- W3173084197 hasRelatedWork W19163398 @default.
- W3173084197 hasRelatedWork W19759200 @default.
- W3173084197 hasRelatedWork W20535288 @default.
- W3173084197 hasRelatedWork W20592577 @default.
- W3173084197 hasRelatedWork W2422317 @default.
- W3173084197 hasRelatedWork W6809237 @default.
- W3173084197 hasRelatedWork W7945670 @default.
- W3173084197 hasRelatedWork W8750365 @default.
- W3173084197 hasRelatedWork W9309986 @default.
- W3173084197 hasVolume "39" @default.
- W3173084197 isParatext "false" @default.
- W3173084197 isRetracted "false" @default.
- W3173084197 magId "3173084197" @default.
- W3173084197 workType "article" @default.